Search Results - influenza

17 Results

Sort By:

Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use

Abstract: This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003). Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1...

Published: 4/8/2024 | Inventor(s): Barry O'Keefe, James McMahon, Toshiyuki Mori

Keywords(s): Anti-Viral, Corona virus, Ebola, Griffithsin, INFLUENZA, O’Keefe, SARS

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing

RNASEH-Assisted Detection Assay for RNA

Abstract: Several viral epidemics – such as the epidemics caused by H1N1 influenza virus, human immunodeficiency virus (HIV), Ebola virus, Zika virus, severe acute respiratory syndrome (SARS) virus, Middle East respiratory syndrome (MERS) virus and SARS-CoV-2 – have profoundly impacted global human health. Early identification of infected and/or infectious...

Published: 8/14/2024 | Inventor(s): G Esta Sterneck, Dipak Poria

Keywords(s): COVID, COVID-19, INFLUENZA, Poria, RNA, RNASEH, SARS-CoV2, Sterneck, Viral RNA

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration

Novel Multivalent Nanoparticle Vaccines

Current seasonal influenza vaccines are designed to elicit immunity to circulating strains of influenza each year. The targeted strains are selected based on predictions of which strains are likely to be predominant in the human population for a given year. This prediction must be made well ahead of the influenza season to allow time for vaccine production...

Published: 7/25/2024 | Inventor(s): Masaru Kanekiyo, Hadi Yassine, Barney Graham

Keywords(s): ARRAY, Broader, DOMAINS, HEMAGGLUTININ, INFLUENZA, Listed LPM Thalhammer-Reyero as of 4/15/2015, MOSAIC, Nanoparticulate, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Receptor-Binding, Receptor-bindingdomains, Spectrum, Vaccine

Category(s): Collaboration Sought > Licensing

Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof

An effective universal influenza vaccine would eliminate the uncertain and costly process of seasonal influenza vaccine development each year. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) are developing immunogens which elicit neutralizing antibodies to the highly conserved stem region of the influenza viral protein...

Published: 7/25/2024 | Inventor(s): Jeffrey Boyington, Hadi Yassine, Peter Kwong, Masaru Kanekiyo, Barney Graham, John Mascola

Keywords(s): Broad, Development, ELICIT, HEMAGGLUTININ, IMMUNE, INFLUENZA, Listed LPM Thalhammer-Reyero as of 4/15/2015, Modified, Nanoparticles, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RESPONSE, Stem

Category(s): Collaboration Sought > Licensing

Protein Nanoparticles for Antigen Display in Vaccines

The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to...

Published: 7/25/2024 | Inventor(s): Dustin McCraw, Audray Harris

Keywords(s): ANTIGEN, DC5BXX, DISPLAY, INFLUENZA, Nanoparticles, Protein, Vaccine, virus

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Materials Available, Application > Vaccines, TherapeuticArea > Infectious Disease

Neutralizing Antibodies to Influenza HA and Their Use and Identification

The effectiveness of current influenza vaccines varies by strain and season, in part because influenza viruses continuously evolve to evade human immune responses. While the majority of seasonal influenza infections cause relatively mild symptoms, each year influenza virus infections result in over 500,000 hospitalizations in the United States and Europe....

Published: 7/25/2024 | Inventor(s): Robert Bailer, Michael Joyce, John Mascola, Peter Kwong, Sarah Andrews, Paul Thomas, Gwo-Yu Chuang, Adam Wheatley, Yi Zhang, James Whittle, Adrian McDermott

Keywords(s): 1, 2, antibodies, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DXXXXX, GROUP, INFLUENZA, Neutralize, That, Their, Viruses, VLXXXX, WJXXXX, WNXXXX, XAXXXX, XKXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease, ResearchProducts > Antibodies, TherapeuticArea > Immunology

Real-Time RT-PCR Assay for Influenza B Lineage Characterization

Influenza B causes significant morbidity and mortality yearly around the world. There are two genetically and antigenically distinct lineages of influenza B that are known to co-circulate within the same influenza season. Currently, the trivalent influenza vaccine only has one influenza B lineage component. CDC researchers developed technology that...

Published: 7/25/2024 | Inventor(s): Stephen Lindstrom, Kai-Hui Wu, LaShondra Berman, Christine Warnes, Shannon Emery

Keywords(s): ASSAYS, B, CHARACTERIZATION, INFLUENZA, LINEAGE, NCIRD, NCIRD-ID, REAL-TIME, RT-PCR

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Real-time RT-PCR assay for Detection of Live Attenuated Influenza Vaccine for A and B Viruses

Upon intranasal vaccination, live attenuated influenza vaccine (LAIV) viruses may replicate within the nose for several days. Current clinical diagnostic tests cannot distinguish between LAIV viruses and multiple influenza viruses in recently inoculated patients that present with respiratory symptoms. This poses a problem for the diagnosis and treatment...

Published: 7/25/2024 | Inventor(s): Stephen Lindstrom, Kai-Hui Wu, LaShondra Berman, Christine Warnes, Bo Shu

Keywords(s): assay, Assays., Attenuated, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDCRM, DA4XXX, Detection, Human, Including, INFLUENZA, LAIV, LAIV-A, LAIV-B, Listed LPM Surabian as of 4/15/2015, Live, NCIRD-ID, PCR, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REAL-TIME, respiratory, RT-PCR, SPECIMENS, States., United, Vaccine, Viruses, VLXXXX, WBXXXX, WIXXXX, XEXXXX, XHXXXX, YDXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Diagnostics, Application > Research Materials, ResearchProducts > Research Equipment

MDCK-based Reporter System for Detection of Influenza Viruses, Antiviral Drug Screening, and Analysis of Neutralizing Antibodies

CDC researchers have developed a Madin-Darby Canine Kidney (MDCK) reporter cell line that is exceptionally permissive for influenza virus replication and provides a highly specific, sensitive approach for the simultaneous detection and isolation of influenza viruses. Simplified antibody neutralization assays and high-throughput antiviral drug screening...

Published: 7/25/2024 | Inventor(s): Zhu Guo, Sandra Perez DeBretschneider, Ruben Donis

Keywords(s): CDC Docket Import, CDC Docket Import CDC Prosecuting, CELL-BASED, Detection, INFLUENZA, MDCK, REPORTER, System, VBXXXX, Viruses, VLXXXX, VOXXXX, WAXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, XEXXXX, XHXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, ResearchProducts > Research Equipment, TherapeuticArea > Immunology, ResearchProducts > Antibodies, Application > Research Materials, Application > Occupational Safety and Health, Application > Vaccines, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Consumer Products

Human Influenza Virus Real-time RT-PCR: Detection and Discrimination of Influenza A (H3N2) Variant from Seasonal Influenza A (H3N2) Viruses, Including H3v and Seasonal H3 Assays

This invention relates to methods of rapidly detecting influenza, including differentiating between type and subtype. CDC researchers have developed a rapid, accurate, real-time RT-PCR assay that has several advantages over culture and serological tests, which require 5 to 14 days for completion; this assay can also be easily implemented in kit form....

Published: 7/25/2024 | Inventor(s): Stephen Lindstrom, Kai-Hui Wu, LaShondra Berman, Bo Shu

Keywords(s): assay, ASSAYS, CDC Docket Import, CDC Docket Import CDC Prosecuting, CIRCULATING, DA4BXX, DA4XXX, DAXXXX, Detection, diagnostic, Diagnostic assay, diagnostic in vitro, discrimination, DXXXXX, Flu, H3, H3N2, H3v, Including, INFLUENZA, ivd, Pandemic, REAL-TIME, RT-PCR, Seasonal, VARIANT, virus, Viruses, VLXXXX, VOXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XCXXXX, XEXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, Application > Occupational Safety and Health, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Consumer Products, Application > Research Materials, Application > Diagnostics

1 2